Exelixis Puts '184 Back in Spotlight With "Dramatic" Prostate Cancer Results
In interim Phase II data, the unpartnered drug reverses bone lesions in metastatic prostate cancer patients.
In interim Phase II data, the unpartnered drug reverses bone lesions in metastatic prostate cancer patients.